Dalriada’s Client Dunad Therapeutics Just Emerged Out of Stealth Mode, Backed by Epidarex Capital
DUNAD Therapeutics Emerges to Develop Next-Generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop